Adaptive Biotechnologies Officer Julie Rubinstein Files Form 144 to Sell 379,777 Shares
Julie Rubinstein, an officer at Adaptive Biotechnologies Corporation, has filed a Form 144 indicating her intent to sell 379,777 common stock shares. The proposed sale, valued at approximately $10.98 million, is slated for October 1, 2026, and will be conducted through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. These shares were acquired via the exercise of stock options, and the transaction is part of a Rule 10b5-1 trading plan established in November 2025.
Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT).
Adaptive Biotechnologies (ADPT) officer Julie Rubinstein has filed a Form 144 notice indicating her intent to sell 379,777 common shares, valued at approximately $10.98 million. These shares will be acquired through stock-option exercises over the next three months. The filing emphasizes compliance with Rule 144 regulations for insider stock sales.
Adaptive Biotechnologies slips as recent rally cools despite no clear new negative catalyst
Adaptive Biotechnologies (ADPT) stock experienced a 3.5% drop, likely due to profit-taking after a strong rally in September. This rally was fueled by positive updates regarding its clonoSEQ minimal residual disease testing business, including its relevance in new international multiple myeloma cure definitions and strengthened NCCN guidelines. Insider trading activity shows significant selling by executives, while institutional investors have both increased and decreased positions.
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rated "Buy" in New Coverage at The Goldman Sachs Group
The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a "Buy" rating and a $35 price target, representing a potential upside of 22.76%. This adds to an overall positive analyst sentiment, with the stock currently holding a "Moderate Buy" consensus rating and an average price target of $28.06. Despite a recent earnings miss, the company's revenue increased by 21.5% year-over-year, although insider sales totaling $43.6 million were noted over the past 90 days.
Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com
This article announces the filing of Form 4 for Adaptive Biotechnologies Corp (ADPT) on September 28. It provides the stock symbol and its current performance (+0.45%), indicating an insider transaction or change in ownership that was reported. The content also includes a broader market overview with various financial indices and commodity prices.
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.1% but Still Overvalued -- GF Score: 72/100
Adaptive Biotechnologies Corp (ADPT) saw its stock fall 3.1% to $28.51, despite a year-to-date increase of 75.5% and a 115.7% rise over the past year. GuruFocus's GF Value™ indicates the stock is 145.4% overvalued compared to its intrinsic value of $11.62, mainly due to unprofitability. The company has a GF Score™ of 72/100, reflecting strong growth but poor profitability and valuation, while insider selling of $121.9M further suggests caution for investors.
Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com
This article reports that Adaptive Biotechnologies Corp (ADPT) filed a Form 4 for September 28th. The filing indicates insider trading activity for the company on that date. The stock symbol ADPT showed a -3.13% change at the time of publication.
Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock By Investing.com
Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 115,406 shares of company stock worth approximately $3.2 million on September 16, 2026. Prior to this, Lo acquired 105,560 shares through option exercises valued at about $1.01 million. The stock is currently trading near its 52-week high, with InvestingPro analysis suggesting it is overvalued.
Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com
This article announces the filing of Form 4 for Adaptive Biotechnologies Corp on September 28, 2026. Form 4 is a U.S. Securities and Exchange Commission filing used to disclose changes in beneficial ownership of securities by company insiders. The article provides the title of the filing and mentions the company's stock symbol ADPT, which showed a slight decrease.
Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock By Investing.com
Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold approximately $3.2 million worth of company stock on September 16, 2026, after exercising stock options. The sales occurred while ADPT stock was trading near its 52-week high, and an InvestingPro analysis indicates the stock might be overvalued. The transactions were conducted under a Rule 10b5-1 trading plan adopted in September 2025.
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Adaptive Biotechnologies (Nasdaq: ADPT) announced that the International Myeloma Society (IMS) has introduced a new consensus definition of cure for multiple myeloma, emphasizing the critical role of highly sensitive measurable residual disease (MRD) testing. The definition requires patients to be in complete remission for five years without treatment, coupled with at least four negative MRD assessments using next-generation sequencing at a sensitivity of 10⁻⁶. Adaptive's clonoSEQ® assay, an FDA-cleared next-generation sequencing MRD test, is highlighted as uniquely positioned to meet the rigorous demands of this new cure standard.
A new myeloma cure definition requires tests able to detect one myeloma cell among a million.
Adaptive Biotechnologies highlighted a new international consensus definition for multiple myeloma cure, requiring five years of complete remission without treatment and at least four negative measurable residual disease (MRD) assessments. These assessments must use highly sensitive tests capable of detecting one myeloma cell among one million. The company's clonoSEQ test is positioned to meet these rigorous standards, marking a significant step towards a clearer understanding of myeloma cure.
Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update
Adaptive Biotechnologies (ADPT) stock is currently trading significantly above its estimated fair value, despite a recent positive update regarding its clonoSEQ testing platform. A Discounted Cash Flow (DCF) model suggests the company's intrinsic value is lower than its current share price of US$29.57, indicating investors are anticipating a strong recovery in cash generation. The recent NCCN guideline update, naming clonoSEQ as a preferred minimal residual disease test, is a key factor driving investor willingness to pay a premium, as it supports expectations for wider clinical adoption.
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 4.4% - Should You Buy?
Adaptive Biotechnologies (NASDAQ:ADPT) stock increased by 4.4% to $29.12, although trading volume was significantly below average. Analysts generally rate the stock a "Moderate Buy" with an average price target of $27.07, and the company exceeded revenue expectations with 21.5% year-over-year growth. However, it missed EPS estimates and remains unprofitable, with insiders selling over 2 million shares worth approximately $47.1 million in the last quarter.
Adaptive Biotechnologies stock hits 52-week high at 28.79 USD
Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $28.79, reflecting significant growth of 117.55% over the past year. Despite this strong performance and revenue growth, InvestingPro analysis suggests the stock might be overvalued. The company recently reported Q2 adjusted losses exceeding analyst expectations but surpassed revenue projections, leading to increased price targets from BTIG and Guggenheim.
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
Adaptive Biotechnologies (ADPT) could see increased repeat orders for its clonoSEQ test following updated National Comprehensive Cancer Network (NCCN) guidelines for multiple myeloma, which now recommend annual testing and testing after later treatment lines. While this presents an opportunity for higher testing frequency and revenue growth, competing tests, payer rules, and the need for attractive reimbursement and cost control pose potential challenges. Hedge fund sentiment, as of Q2 2026, showed a slight decrease in holdings of ADPT before these new recommendations were announced.
Bank of America Corp DE Makes New Investment in Adaptive Biotechnologies Corporation $ADPT
Bank of America Corp DE has acquired 1.73 million shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) worth approximately $37.1 million, establishing a 1.08% stake in the company. Institutional investors now own 99.17% of the company's stock. Despite missing earnings per share estimates, Adaptive Biotechnologies reported strong revenue growth, and analysts generally maintain a "Moderate Buy" rating with a consensus price target of $24.42, although insider selling has been notable.
Tidal Investments LLC Takes $855,000 Position in Adaptive Biotechnologies Corporation $ADPT
Tidal Investments LLC has acquired an $855,000 stake in Adaptive Biotechnologies Corporation (ADPT) during the second quarter, making it one of several institutional investors increasing their positions. Despite the company reporting a quarterly loss that exceeded estimates, its revenue surpassed expectations. Analysts currently rate ADPT as a "Moderate Buy," even though insiders have recently sold a significant amount of company stock.
Adaptive Biotechnologies (ADPT) HR chief sells over 100,000 shares under preset plan
Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and sold 115,406 shares of common stock on September 16, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were conducted at weighted average prices of $28.02 and $28.57 per share, following the exercise of 105,560 options at various prices. The transaction resulted in approximately $3.24 million in gross sale proceeds, with about $1.01 million in exercise costs.
Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells shares under pre-set trading plan
Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 1,195 shares of common stock at $27.00 per share on September 15, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Bobulsky directly holds 395,794 shares of ADPT.
Adaptive biotechnologies chief commercial officer sells $32,265 in shares.
Susan Bobulsky, Chief Commercial Officer at Adaptive Biotechnologies Corp, sold 1,195 shares worth $32,265 on September 15, 2026. The stock has since risen to $28.55, near its 52-week high, with a 107% return over the past year. Analysts have raised price targets for the company due to strong revenue growth and performance in its minimal residual disease business.
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Adaptive Biotechnologies announced significant updates to the NCCN Guidelines for Multiple Myeloma, which now include a dedicated framework for routine minimal residual disease (MRD) assessment. The updated guidelines strengthen recommendations for MRD testing, specifically naming clonoSEQ as an FDA-cleared assay with a preferred 10⁻⁶ sensitivity. These changes are expected to support more informed treatment decisions and personalized patient care throughout the disease journey.
Alert incorrectly tagged to Adaptive Biotechnologies withdrawn
MarketScreener published an alert that was incorrectly tagged to Adaptive Biotechnologies and has since withdrawn it. The article, which was reserved for members, was originally published on September 17, 2026, at 07:23 am EDT. This news item is listed alongside other recent company updates, including insider stock sales and NCCN guideline updates for multiple myeloma.
Adaptive Biotechnologies stock hits 52-week high at 26.89 USD By Investing.com
Adaptive Biotechnologies (ADPT) stock reached a new 52-week high of $26.89, closing at $26.90. This performance is backed by an 89.45% 1-year total return and robust 50.13% revenue growth over the last twelve months. Analysts have revised earnings upwards, indicating strong market confidence, although InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value.
Adaptive Biotechnologies stock hits 52-week high at 26.89 USD By Investing.com
Adaptive Biotechnologies (ADPT) stock has reached a new 52-week high of $26.89, closing at $26.90, reflecting an 89.45% 1-year total return and 50.13% revenue growth. Seven analysts have revised earnings upwards, indicating strong market confidence despite the stock being potentially overvalued according to InvestingPro. Recent Q2 revenues of $71.6 million surpassed estimates, and analysts from BTIG and Guggenheim raised price targets due to strong growth in its clonoSEQ MRD business.
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. Management is scheduled to hold a fireside chat on September 15, 2026, at 1:50 p.m. PT / 4:50 p.m. ET, with a live and archived webcast available on the company's investor website. The company aims to translate the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases like cancer and autoimmune disorders.
Adaptive Biotechnologies director Owen sells $249,990 in stock. By Investing.com
Katey Einterz Owen, a director at Adaptive Biotechnologies Corp (ADPT), sold 9,615 shares of company stock for $249,990 on August 26, 2026, when the stock was near its 52-week high after an 89% gain. InvestingPro analysis indicates the stock may be overvalued. This sale occurred despite recent positive analyst sentiment and strong Q2 revenue, though the company missed adjusted EPS estimates.
Adaptive Biotechnologies stock hits 52-week high at $26.63
Adaptive Biotechnologies (ADPT) stock recently hit a 52-week high of $26.63, reflecting a 1-year total return of 101.7%. Despite this strong performance, InvestingPro analysis suggests the stock might be overvalued at its current $4.18 billion market capitalization. The company reported a mixed Q2, with an adjusted loss per share wider than estimates but revenue exceeding expectations, driven by a 49% year-over-year growth in its core minimal residual disease business.
Adaptive Biotechnologies director Robert Hershberg sells $748k in shares
Robert Hershberg, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 30,664 shares of the company's common stock for a total of $748,208 on August 18, 2026. These sales occurred after Hershberg exercised stock options to acquire 15,000 shares. The company recently reported mixed Q2 results with revenue exceeding estimates, and BTIG and Guggenheim have raised their price targets on ADPT shares.
Adaptive Biotechnologies director Robert Hershberg sells $748k in shares
Robert Hershberg, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 30,664 shares totaling $748,208 on August 18, 2026. These sales occurred after Hershberg acquired 15,000 shares through option exercises at a much lower price. The stock's current valuation appears overvalued according to InvestingPro, despite a 107% return over the past year and recent positive analyst ratings.
Bank of America Corp DE Acquires 421,645 Shares of Adaptive Biotechnologies Corporation $ADPT
Bank of America Corp DE has increased its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 52.3% in the first quarter, acquiring an additional 421,645 shares and bringing its total holdings to 1,227,917 shares valued at $17,043,000. This comes amidst mixed sentiment for ADPT, with analysts maintaining a "Moderate Buy" consensus and significant institutional ownership, yet the company reported a quarterly EPS miss and experienced notable insider selling.
Adaptive Biotechnologies (NASDAQ:ADPT) Director Robert Hershberg Sells 30,664 Shares of Stock
Robert Hershberg, a director at Adaptive Biotechnologies (NASDAQ:ADPT), sold 30,664 shares of the company's stock for approximately $748,202, reducing his direct holdings by nearly 40%. The sale occurred as ADPT shares traded near their 12-month high, despite the company missing EPS estimates in its recent quarterly report. Analysts maintain a "Moderate Buy" rating with a consensus price target of $24.42, and several firms have recently raised their price targets.
Adaptive Biotech (NASDAQ: ADPT) ex-officer to sell 402,160 shares
Adaptive Biotechnologies Corp (ADPT) former officer Harlan Robins plans to sell 402,160 shares of common stock, valued at over $10.2 million, through Goldman Sachs & Co. LLC. These shares were acquired as compensation via stock options in 2022 and are slated for a cashless exercise/same-day sale. The filing also details multiple previous open-market sales by Robins within the last three months.
Adaptive Biotechnologies (NASDAQ: ADPT) director exercises option at $6.32 strike
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg exercised a stock option for 15,000 shares at $6.32 per share on August 18, 2026. He then sold a total of 30,664 shares in two transactions at weighted average prices of $24.39 and $24.41. The option was fully vested and would have expired on October 18, 2026.
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares
Adaptive Biotechnologies CEO Chad Robins sold approximately $14.88 million worth of company common stock on August 17 and 18, 2026, following the exercise of stock options. These sales occurred as ADPT stock traded near its 52-week high after a 107% gain over the past year, though InvestingPro analysis suggests the stock is currently overvalued. Despite an earnings miss, Adaptive Biotechnologies reported strong Q2 revenue growth, leading BTIG and Guggenheim to raise their price targets for the company.
Adaptive Biotechnologies director Neupert sells $3.1m in stock
Adaptive Biotechnologies Corp (NASDAQ:ADPT) director Peter M. Neupert sold 124,690 shares of common stock for $3.1 million on August 17, 2026. This transaction occurred while the stock trades near its 52-week high after a significant 107% return over the past year. InvestingPro analysis suggests the stock may be overvalued, despite recent positive analyst ratings and strong revenue growth reported by the company.
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares
Adaptive Biotechnologies Corp (NASDAQ:ADPT) CEO Chad M. Robins sold approximately $14.88 million worth of company stock on August 17 and 18, 2026, following the exercise of stock options. The sales occurred as the stock neared its 52-week high after a significant 107% gain over the past year. Despite an adjusted loss per share in Q2, the company reported strong revenue growth, leading BTIG and Guggenheim to raise their price targets for ADPT.
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares By Investing.com
Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold approximately $14.88 million worth of company stock on August 17 and 18, 2026, following the exercise of stock options. The sales occurred as the stock neared its 52-week high after a 107% gain over the past year. Despite a recent earnings miss, analysts from BTIG and Guggenheim have raised their price targets for Adaptive Biotechnologies, citing strong revenue growth and impressive performance in its core minimal residual disease business.
Adaptive Biotechnologies director Neupert sells $3.1m in stock
Peter M. Neupert, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 124,690 shares of common stock for over $3.1 million on August 17, 2026, after exercising options for 15,000 shares. The stock is near its 52-week high, having returned 107% in the past year, though some platforms suggest it is overvalued. This follows recent positive news for the company, including exceeding revenue expectations and price target increases from BTIG and Guggenheim due to strong growth in its minimal residual disease business.
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 278,676 Shares
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins sold 278,676 shares of the company's stock for over $6.82 million on August 18th, reducing his direct stake by 11.33%. Despite a quarterly loss of $0.25 per share, which missed analyst expectations, the company's revenue increased by 21.5% year-over-year. Analysts maintain a "Moderate Buy" rating with an average price target of $24.42, and institutional investors own a significant 99.17% of the stock.
Adaptive Biotechnologies (ADPT) director sells stock after option exercise
Peter M. Neupert, a director at Adaptive Biotechnologies Corp (ADPT), reported exercising 15,000 stock options at $6.32 per share and subsequently selling 124,690 shares of common stock. The sales were conducted in open-market transactions at weighted average prices between $25.10 and $25.27 per share, generating approximately $3.14 million in gross proceeds. This transaction fully exhausted the exercised option grant and significantly reduced his direct common stock holdings.
Adaptive Biotechnologies (ADPT) CEO sells 600K shares after exercising options
Adaptive Biotechnologies Corp (ADPT) CEO and Chairman Chad M. Robins exercised stock options for 600,000 shares and subsequently sold all 600,000 shares in open-market transactions on August 17 and 18, 2026. The options were exercised at $6.55 per share, and the shares were sold at weighted average prices between approximately $24 and $26 per share. This exercise-and-sell pattern resulted in an approximate pre-tax spread of $10.95 million for Robins.
Adaptive Biotechnologies (NASDAQ: ADPT) ex-officer plans new share sale
Harlan Robins, a former officer of Adaptive Biotechnologies (NASDAQ: ADPT), plans to sell up to 215,632 shares of common stock through Goldman Sachs & Co. LLC under Rule 144, valued at approximately $5.5 million. The shares were acquired as compensation via stock options in March 2022 and the disposition is described as a cashless exercise and same-day sale. The filing also details multiple prior stock sales by Robins over the last three months.
Adaptive Biotechnologies stock hits 52-week high at 26.16 USD
Adaptive Biotechnologies (ADPT) stock reached a new 52-week high of $26.16, marking a nearly 100% change over the past year. Despite this strong performance and investor confidence, InvestingPro analysis suggests the stock might be overvalued with high volatility. The company recently reported a Q2 earnings miss but exceeded revenue expectations, leading BTIG and Guggenheim to raise price targets and maintain Buy ratings.
66,000 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Handelsbanken Fonder AB
Handelsbanken Fonder AB recently acquired 66,000 shares of Adaptive Biotechnologies Corporation ($ADPT) valued at approximately $1.42 million. This purchase is part of broader institutional investor activity, with hedge funds and institutions owning 99.17% of the company. Despite positive analyst ratings and strong revenue growth, the company missed earnings per share estimates, and insiders have sold a significant number of shares recently.
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans more sales after $7.96M already sold
Adaptive Biotechnologies insider Chad Robins has filed a Rule 144 notice to sell 278,676 shares of common stock, valued at $6.84 million, through Goldman Sachs & Co. LLC. This follows prior sales of 321,324 shares worth $7.96 million over the last three months. The shares for the new sale were originally granted as stock options on February 7, 2018, and will be disposed of via a cashless exercise/same-day sale.
Adaptive Biotechnologies (ADPT) ex-officer plans cashless option share sale
A former officer of Adaptive Biotechnologies (ADPT), Harlan Robins, intends to sell 261,044 shares of common stock under Rule 144, valued at approximately $6.4 million. These shares were acquired as stock option compensation and will be sold via a cashless exercise and same-day sale through Goldman Sachs & Co. LLC. The filing also reveals multiple prior stock sales by Robins within the last three months, totaling over 1.2 million shares.
Adaptive Biotechnologies (NASDAQ: ADPT) director plans to resell 30,664 shares
Adaptive Biotechnologies (ADPT) director Robert M. Hershberg has filed a Form 144 notice to potentially resell up to 30,664 shares of common stock. The proposed sale has an aggregate market value of $748,303.36 and includes shares from a stock option exercise and restricted stock. This filing is a notice of intent and does not confirm the actual execution of the transactions.
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins, co-founder of Adaptive Biotechnologies, has launched a new Bellevue startup called Harell Data with $15 million in funding. The company aims to provide a secure platform for data creators to commercialize their proprietary research datasets by connecting them with AI modelers, addressing the current lack of fair compensation for high-quality scientific data used in AI development. Harell Data will allow machine learning groups to train models without accessing the raw data directly, offering revenue sharing to data owners and enabling solutions to complex scientific problems across various disciplines.
Adaptive Biotechnologies (NASDAQ: ADPT) lines up six-figure share sale for 2026
Adaptive Biotechnologies Corp. (ADPT) has filed a Form 144, indicating a planned sale of 124,690 common shares valued at approximately $3.14 million. The sale, scheduled for August 17, 2026, will be handled by Morgan Stanley Smith Barney LLC and includes shares from stock option exercises, restricted stock grants, and previously exercised shares. This filing provides transparency regarding future stock transactions by insiders.
